Clarius Group LLC Has $212,000 Stake in GSK plc (NYSE:GSK)

Clarius Group LLC lowered its position in shares of GSK plc (NYSE:GSK) by 26.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,514 shares of the pharmaceutical company’s stock after selling 1,997 shares during the period. Clarius Group LLC’s holdings in GSK were worth $212,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Register Financial Advisors LLC acquired a new position in shares of GSK during the first quarter worth $31,000. Richardson Financial Services Inc. acquired a new position in GSK during the 4th quarter worth about $40,000. Newbridge Financial Services Group Inc. bought a new stake in shares of GSK in the 1st quarter valued at about $49,000. Concord Wealth Partners increased its stake in shares of GSK by 69.7% in the first quarter. Concord Wealth Partners now owns 1,436 shares of the pharmaceutical company’s stock valued at $62,000 after buying an additional 590 shares during the period. Finally, YHB Investment Advisors Inc. acquired a new stake in shares of GSK in the first quarter valued at about $62,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Stock Up 0.6 %

Shares of GSK stock traded up $0.24 during trading on Friday, reaching $40.26. 2,176,279 shares of the company traded hands, compared to its average volume of 3,586,379. The firm has a market capitalization of $83.44 billion, a PE ratio of 14.50, a P/E/G ratio of 1.32 and a beta of 0.64. GSK plc has a 1-year low of $33.67 and a 1-year high of $45.92. The company has a 50 day moving average price of $39.85 and a 200-day moving average price of $41.38. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.58.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be issued a dividend of $0.3843 per share. The ex-dividend date of this dividend is Friday, August 16th. This represents a $1.54 annualized dividend and a dividend yield of 3.82%. This is a positive change from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio is currently 54.71%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on GSK shares. The Goldman Sachs Group assumed coverage on GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price on the stock. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Jefferies Financial Group lifted their target price on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Finally, Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, GSK currently has a consensus rating of “Buy” and a consensus target price of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.